Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.
Industry, Sector and Symbol:
Average Prices:- 50 Day Moving Avg: A$0.25
- 200 Day Moving Avg: A$0.28
P/E:- Trailing P/E Ratio: 5.34
- P/E Growth: 0.00
Dividend:
Profitability:- Net Margins: 44.12%
- Return on Equity: 26.73%
- Return on Assets: 22.55%
Frequently Asked Questions for Acrux Limited (ASX:ACR)
What is Acrux Limited's stock symbol?
Acrux Limited trades on the ASX under the ticker symbol "ACR."
Who are some of Acrux Limited's key competitors?
Some companies that are related to Acrux Limited include Adelaide Brighton (ABC), AGL Energy Ltd (AGK), AGL Energy Ltd (AGL), Alacer Gold Corp - CDI (AQG), ALS Ltd (ALQ), Alumina Limited (AWC), Amcor Limited (AMC), AMP Limited (AMP), Ansell Limited (ANN), APA Group (APA), Aquarius Platinum Limited (AQP), Ardent Leisure Group (AAD), Aristocrat Leisure Limited (ALL), Arrium Ltd (ARI), Asciano Ltd (AIO), ASX Ltd (ASX), Atlas Iron Limited (AGO) and Augend Ltd (TTN).
Who are Acrux Limited's key executives?
Acrux Limited's management team includes the folowing people:
- Michael Kotsanis, Chief Executive Officer, Managing Director, Executive Director
- Tim Bateman, Chief Financial Officer, Company Secretary
- Nina Webster, Commercial Director
- Felicia Colagrande, Product Development and Technical Affairs Director
- C O'Sullivan, Portfolio Director
- Ross Dobinson, Non-Executive Chairman of the Board
- Geoffrey E.D. Brooke M.D., Non-Executive Director
- Simon Green, Non-Executive Director
- Timothy Charles Oldham, Non-Executive Director
MarketBeat Community Rating for Acrux Limited (ASX ACR)MarketBeat's community ratings are surveys of what our community members think about Acrux Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Acrux Limited (ASX:ACR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Acrux Limited (ASX:ACR)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Acrux Limited (ASX:ACR)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Acrux Limited (ASX:ACR)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Acrux Limited (ASX:ACR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Acrux Limited (ASX:ACR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Acrux Limited (ASX:ACR)
Latest Headlines for Acrux Limited (ASX:ACR)
| Source: |
|
